• Third consecutive quarter of positive net cash flow
• Operating cash flow of NZ$1.7 million
• Strong cash receipts of NZ$22.5 million
• Reaffirms FY26 guidance of NZ$92-100 million revenue and NZ$5-8 million EBITDA

Aroa Biosurgery Limited (ASX: ARX) has reported its results for the quarter ended 30 June 2025. The company posted its third consecutive quarter of positive net cash flow, with cash flows from operations of NZ$1.7 million, supported by strong cash receipts of NZ$22.5 million during the quarter. Net cash outflows from investing activities were NZ$0.9 million, primarily reflecting routine capital expenditure. Total cash on hand increased by NZ$0.2 million, and the company ended the quarter with a cash balance of NZ$22.2 million. The company remains debt-free. Aroa reaffirmed its full year FY26 total revenue guidance of NZ$92-100 million (growth of 10-20% on FY25) and normalised EBITDA of NZ$5-8 million (growth of 19-90% on FY25). The company saw sustained growth in sales of its high-margin Myriad product family, consistent with expectations. During the quarter, two new peer-reviewed studies were published, including a large real-world study on the efficacy of Aroa's Endoform product in treating venous leg ulcers.

Aroa reaffirms full year FY26 total revenue guidance of NZ$92-100 million (growth of 10-20% on FY25) and normalised EBITDA of NZ$5-8 million (growth of 19-90% on FY25).